Opertech Bio announced the publication of their new research article, “Sodium-dependent glucose co-transport proteins (SGLTs) are not involved in human glucose taste detection," published in the November 18, 2024 issue of the peer-reviewed journal PLOS ONE.
Pennovation Works Managing Director, Denita Henderson, had the chance to sit down with Chris from BioBuzz during the Philly Builds Bio+ conference to discuss why Pennovation Works is the place "where ideas go to work".
A great time was had by all at the annual Pennovation Works and GRASP Lab pumpkin paint and sipping event! Attendees unleashed their creativity by painting pumpkin swhile enjoying fall-inspired treats and networking.
Congratulations to Pennovation Center members, Matt Williams and Arai Yegrosa from Philly Unlimited, the non-profit social impact arm of Tech Difficulties, on winning Best Idea at the Philadelphia Open Innovation Tournament!
Interius Biotherapeutics announced that the first study participant has been dosed in INVISE, its first-in-human Phase 1 clinical trial of INT2104, a first-in-class gene therapy that delivers a CAR transgene to generate effector CAR-T and CAR-NK cells in vivo for the targeting of CD20-positive B cells for the treatment of B-cell malignancies.
Pennovation Works was proud to be a sponsor of the 1682 Conference being held at the Five Below headquarters in October.
And we're excited to announce that Pennovation Center member, Tejas Agarwal, Founder and CEO of Sahay AI, won the Venture Awards pitch competition that was held during the event. Congratulations Tejas and team!
The Philly Builds Bio+ 3rd Annual “Bridging the Gap to Commercialization” Symposium took place in October at the Crystal Tea Room. It was a day filled with over 50 panelists discussing innovations in Philadelphia's life sciences sector.
According to new data from PitchBook, the University of Pennsylvania has ranked among the top schools in the world for producing future founders.
Out of those founders, the university has produced 596 female founders who have raised a combined $12.2 billion.
The U.S. National Science Foundation (NSF) announced an $18 million funding allocation to Infini Fluidics, Penn’s schools of engineering and medicine, Drexel University, the Children’s Hospital of Philadelphia, and the University of Puerto Rico, Mayagüez campus (RUM) to develop the NSF AIRFoundry.
NSF AIRFoundry is one of five newly created BioFoundries, each of which will have a different focus. Bringing together researchers from InfiniFluidics and other institutions, they will work closely to improve the design and manufacture of lipid nanoparticles (LNPs).
Congratulations to Interius BioTherapeutics who recently announced they raised $67 million in funding. This Series B round will support clinical development of the company's lead gene therapy candidate.
Read more about their funding.